Information Asymmetry intelligence across Pharma, Semiconductors. 100 total signals, 70 actionable. Our signal engine scans narrative pressure, identifies information asymmetry, and publishes directional intelligence with conviction scoring and edge quality assessment.
Samsung SDI's Mercedes and ESS drumbeat: a Korea-first repricing window in a choppy tape
The system is calling Samsung SDI LONG because the mechanism is supplier-positive: reported EV supply wins and an ESS contract disclosure imply incremental volume visibility and a path to narrative repair beyond the 'EV chasm' framing. This is sti...
SK hynix pricing power isn't just HBM: LTAs and allocation squeeze bleeding into 'normal' DRAM
The system is LONG SK hynix with high conviction because the shortage mechanism is supplier-positive and, crucially, now described as contract-structure driven rather than a vague 'cycle' trope. The upstream validation says this is confirmed and i...
Intel's foundry narrative gets operational texture: yields, packaging, and the 'show me the custo...
This is a LONG call on Intel with high conviction because the signal resolved from 'manufacturing narrative' into a practitioner-anchored operational claim: 18A yield issues and supply constraints are being discussed with specific detail, and the ...
Qualcomm Re-Opens the Samsung Foundry Door - A Small Headline That Can Still Hit TSMC's Multiple
The core claim is not that Qualcomm has switched foundries, but that it is credibly re-engaging Samsung for future 2nm Snapdragon manufacturing. That matters for TSMC because the market trades foundry share stories on headlines: even a partial sec...
Telehealth drug access is colliding with enforcement reality - and the sector proxy is the clean ...
This is a channel-economics short expressed through a biotech proxy: regulators and practitioners are increasingly framing telehealth/DTC drug access as a compliance choke-point, where discount mechanics, promotional claims, and compounding distri...
Intel's earnings beat is being traded as a sector-beta shock, not a politics story
This signal resolves to a simple tradable mechanism: an Intel earnings beat and guidance framing that the market is treating as a semiconductor-beta impulse, best expressed via SMH rather than overfitting to the label's political wrapper. Validati...
Psychedelics EO: the edge is reading the document, not trading the meme
This is a LONG proxy call on the biotech/pharma complex (XBI/IHE), driven by a policy catalyst that can re-rate the psychedelic cohort via perceived time-to-approval compression. The edge is not that an executive order exists (that headline is alr...
ClinicalTrials.gov enforcement is shifting from etiquette to liability - broad, quiet, and negati...
The cleanest, most primary-sourced signal in the book: FDA outreach on March 30, 2026 to more than 2,200 sponsors and investigators linked to more than 3,000 trials missing results reporting, with explicit enforcement pathways referenced. 7A takes...
Nokia is getting re-framed as an AI optical transport play, and the retail detail is ahead of bro...
The upstream call is LONG: Nokia optical and IP transport sales are being pulled by AI data-centre buildouts, with a plausible re-rating pathway as the market stops treating NOK as a legacy telco vendor and starts treating it as an AI infrastructu...
Micron's AI-memory surge: a bullish mechanism with a validation gap
The call is LONG Micron because the mechanism is supplier-positive: AI-linked memory demand and mix shift can drive revenue and profitability upside, and the due diligence layer explicitly frames the theme as tied to the current guidance cycle and...
China just put Hensoldt on an export-control list - the market will price the uncertainty before ...
This is a clean SHORT mechanism on a named equity: a PRC dual-use export restriction that explicitly includes Hensoldt introduces operational friction, delivery timing risk, and a higher uncertainty discount for defence-electronics supply chains. ...
FCC router authorisation confusion is turning into a real demand and shelf-space shock
The upstream direction is SHORT via XLK as a proxy expression: the mechanism is regulatory authorisation uncertainty around consumer router approvals and exemptions, which can delay new-model launches, raise compliance costs, and create distributi...
Novo Nordisk's 'Unknown' Cluster Looks Like Noise - Which Can Still Be Bullish If The Overhang Is...
The signal here is less a concrete event and more a pattern: Novo Nordisk repeatedly co-mentioned across a bundle tagged with an 'unknown' label, with no Tier-1 pickup in the original bundle and a contained posture. 7.2's synthesis materially weak...
TurboQuant is not a memory-demand kill switch - it is a scope-limited efficiency story that can s...
This is a LONG call expressed through SMH: the upstream synthesis argues that TurboQuant-style efficiency news is being misread as broad memory demand destruction, when the technical scope is narrower (KV-cache compression in inference) and can co...
India’s Memory-Driven Handset Squeeze: Xiaomi Faces a Volume-Margin Double Hit Before the Street ...
This is a straight SHORT call on Xiaomi: the signal is that India’s smartphone market is hitting a multi-year low while memory costs are rising, which is the worst mix for a volume-driven, promo-heavy OEM footprint. The mechanism is buyer-side pai...
India handset unit recession as the hidden consumer-semi headwind: expressing it via SMH
This is a SHORT call expressed through the SMH proxy: the thesis is that memory-cost pass-through can drive price-led demand destruction in a price-sensitive market like India, and that handset unit pressure is an underappreciated offset to the se...
Korea GDP surprise is being narrated as semiconductor-export led - the trade is semi beta with an...
Upstream resolves the direction to LONG via SMH: the core mechanism is that an export-led Korea GDP surprise, explicitly framed in community digestion as semiconductor/IT component driven, supports the semiconductor cycle narrative and keeps beta ...
Korean 'AI components' euphoria, but a sloppy binding: why this is still LONG via SMH
The direction is LONG because the intended mechanism is supplier-positive: AI component demand driving utilisation and expansion signals across the Korea supply chain. The catch, explicitly flagged upstream, is that the story may be mis-specified ...
Oil-to-EV-to-semiconductors is a real channel, but the Toyota link still needs clean causality
The system is LONG via proxy because the hypothesised buyer-positive mechanism is intuitive: higher fuel prices can pull forward electrified demand, and electrification increases semiconductor content per vehicle. The call is framed as second-orde...
Section 232 drug tariffs: the headline says 100%, the market risk is the messy transmission
This is a policy-volatility short on a pharma proxy: a primary White House artefact (dated April 2, 2026) is cited in due diligence as the anchor for a Section 232 tariff regime on patented pharmaceuticals and ingredients, with the rest of the eco...
Mac mini stockouts look like a near-term shipment timing risk - the market will guess supply befo...
The upstream call is SHORT on AAPL: observable stockouts and extended lead times for Mac mini (and related configurations) imply shipment and revenue timing risk in the near term, regardless of whether the root cause is true memory tightness or Ap...
DeepSeek's $10B funding chatter: a sentiment tail for AI risk appetite more than a hard compute o...
The system is LONG via proxy because the reported China foundation-model valuation momentum can lift AI risk appetite and spill over into semiconductor sentiment, even if the direct compute demand link is debated. The key point is that this remain...
Biotech enforcement risk is back in the headlines - and the spillover is the point
This signal is not about one issuer; it is about a sector-level premium for disclosure integrity. The cluster is dominated by enforcement and litigation narratives: alleged trial misrepresentation, securities fraud themes, and a repeating pattern ...
Revolution Medicines: the stock can celebrate survival, but the short is about tolerability ceilings
This is an idiosyncratic biotech short: the thesis is that efficacy headlines can be true while the commercial ceiling is set by toxicity, discontinuations, and dose-intensity constraints in first-line metastatic pancreatic cancer. 7A stays SHORT ...
FDA Sends 2,200 Trial-Disclosure Notices - Merck Gets Pulled Into the Blast Radius
The core event is real and time-stamped, but the market mapping is messy: the FDA publicly described a broad ClinicalTrials.gov enforcement push (not a named Merck action), including notices sent on 30 March 2026 and a reminder press announcement ...
Kratom harm data is creeping into the mainstream - the retail distribution angle is the equity hook
The signal is a risk-anomaly bundle around kratom toxicity and the regulatory/litigation narrative that tends to follow rising poison-centre and CDC-style datapoints. 7A expresses it as a SHORT through CVS as the named retail/distribution channel ...
The law-firm wave is not the story - the story is revenue-quality doubt that can linger in small-...
This is an emerging cluster (rating D) capturing a familiar sequence: catalyst allegation, drawdown, then a burst of solicitation-style investigation releases. 7A is still directionally SHORT on a biotech proxy because even when the legal content ...
The 'SEC rare disease advancement' story looks like class-action template noise - but the proxy s...
The pipeline is flagging a contained-but-high-noise cluster where "SEC" and "rare disease" language appears alongside a familiar PR-wire/law-firm ecosystem (Rosen/Hagens Berman style), with multiple small/mid-cap biotech names name-checked. 7.1 va...
Genetic data lawsuits are becoming a business-model attack - and this one has a primary artefact
This is a legal and reputational short on a biotech proxy: class action allegations that genetic testing data was collected and disclosed without proper consent, framed as a direct challenge to a data-flywheel model. 7A routes it with an IGNITE pr...
The Lawsuit-Alert Wave Is Back - Biotech Risk Premium Creeps Higher Through the Side Door
This is not a single-name blow-up; it is a sentiment mechanic. The pipeline is flagging a renewed burst of securities-law activity marketing itself as investigations/alerts across multiple healthcare and biotech issuers. Even when the underlying m...
CMPS is the cleanest single-name read-through from the psychedelics EO
This is a LONG on Compass Pathways (CMPS) because it is a named, tradeable developer sitting closest to the “policy prioritisation” narrative that investors can translate into probability-weighted timeline compression. The mechanism sign is positi...
Data-centre build friction is turning into policy friction, and the first trade expression is tec...
Upstream resolves to SHORT via XLK: the mechanism is not 'AI demand is dead', it is that regulatory scrutiny and moratoria narratives can slow the timing of data-centre builds, shifting capex recognition and the revenue timing of the AI stack. Tha...
US-Korea tech-security pressure as a volatility tax: why this is a SHORT expression via SMH
The direction is SHORT because the mechanism is supplier-negative: policy friction and regulatory barriers can slow deployments, raise compliance costs, and widen risk premia, even without immediate company guidance changes. The system routes this...
Medpace lawsuit risk: the alpha isn't the lawsuit - it's whether this stays in PR-land or hits re...
This is a contained litigation headline-risk signal: a securities class action filed against Medpace has a plausible pathway to multiple compression and management distraction, and it often propagates through a predictable distribution chain (Glob...
A New Opioid 'Resistance' Narrative Is A Headline Risk For Naloxone - Even If Demand Goes Up
This is an emerging public-health-to-market narrative: officials and forensic bodies flag an opioid analogue (labelled cychlorphine/cyclorphine in media) with claims of incomplete naloxone response. For a branded naloxone complex, that is a classi...
Lupin's $30m Humana Settlement Is Small Dollars But A Real Antitrust Overhang Reminder
The core fact pattern is straightforward: multiple sources describe Lupin's US unit settling Humana antitrust claims for about $30m. 7A expresses it SHORT via sector proxies, which is a bet on risk premia rather than on cash math: settlement headl...
Xi'an semiconductor export strength: a bullish datapoint that still needs the primary customs table
The system resolves LONG because the mechanism leans bullish: semiconductor-linked foreign trade growth can indicate genuine demand pull or export competitiveness, and this looks under-discussed in English-language investing surfaces. It is expres...
A Real Psychedelics Executive Order - Policy Signal First, Fundamentals Later
Unlike most policy chatter, there is a primary artefact: the White House published an executive order titled "Accelerating Medical Treatments for Serious Mental Illness" dated 18 April 2026, with explicit intent to prioritise psychedelic research ...
The biotech lawsuit cluster is a sentiment tax - and it tends to hit XBI first
This is a SHORT proxy call via XBI because clustered class-action/investigation headlines function as a behavioural overhang in small/mid-cap biotech: they sap dip-buying and keep financing optionality in question. The mechanism sign is negative w...
Power Wall as a Narrative Trap: A Broadcom/VMware Short That Needs a Real Customer-Delay Artefact...
The call is SHORT AVGO on a simple mechanism: if AI deployment velocity is capped by power availability, the near-term “AI stack” expansion narrative can run ahead of what can actually be built and billed. But the signal is fragile because it risk...
Lilly 'insider advantage in M&A' reads like template litigation until a named transaction appears...
This is a governance/headline-risk motif: allegations of insider advantage around M&A can pressure a high-multiple mega-cap because they create a "what else" question even when the claim is thin. The direction is SHORT because governance smear nar...
FDA 'streamlining' for genome editing: if process uncertainty compresses, biotech beta gets a val...
The bullish read here is straightforward: clearer FDA frameworks and operational experimentation around genome editing and ultra-rare/individualised therapies can reduce perceived regulatory randomness, and when the Street feels the rules of the g...
The Rosen-Law-Firm 'Wave' Is Mostly Solicitation - But It Still Acts Like A Sector Volatility Tax
This is a meta-signal about the legal-information surface in small/mid biotech: clustered 'investigation' and 'deadline' press releases that can look like real escalation even when they are attorney advertising. 7A keeps the call SHORT (expressed ...
ASCO season is a risk-appetite pulse, not a single trade - but XBI gets the volatility
This is a LONG proxy call (XBI/IHE) on the idea that ASCO-driven event density can pull forward attention and risk appetite in oncology-heavy names before full-side modelling catches up. The mechanism here is expectation resets and attention shock...
A Korea Policy Headline with Real Beta: If This Turns into Rules, EWY/SMH Wear the Volatility First
The directional call is SHORT on the proxy basket (SMH/EWY) because the mechanism is regulatory uncertainty: US pressure on Korea about China tech reliance and “regulatory barriers” is the kind of headline that can widen risk premia before any rul...
UK Power-Cost Offshoring: A Survey Signal That Could Turn into a Real Capex Timing Hit for AI Inf...
This is a SHORT call on proxies (SMH/TLT) framed as timing risk: if high electricity costs and constrained infrastructure push UK firms to deploy AI projects abroad, the near-term build-out schedule gets noisier and delay risk rises. For semis, th...
Roundup litigation isn't new - the trade is the calendar: Supreme Court posture and settlement me...
This is a classic litigation-overhang setup: not a discovery story, a probability-weighted legal inflection story. The direction is SHORT because the base case is that legal uncertainty keeps a risk premium embedded, and adverse timeline surprises...
UK ASA clamps down on weight-loss medicine ads: a real channel constraint that investors still un...
This is a clean regulator-driven marketing enforcement story, and those matter because GLP-1 demand capture is increasingly mediated by online clinics, influencer-adjacent funnels, and grey marketing. The direction is SHORT because enforcement is,...
A Form 483 is not a warning letter - but it is the optionality that creates the drawdown if it es...
The core thesis is classic India-pharma regulatory optionality: a Form 483 introduces a distribution of outcomes that can widen perceived risk premia, especially if investors start pricing a path to warning letter or import constraints. The direct...
AvertD is an FDA-cleared artefact - but the investable read-through skews negative
This is a SHORT proxy call via IHE because the dominant emerging narrative around the blood-based OUD-risk test is controversy and backlash risk rather than clean adoption upside. The mechanism is reputational and policy: even if the intended use ...
A Xi’an Trade ‘Dark Horse’ Print: If the Numbers Are Real, the Semiconductor Cycle Narrative Tigh...
The direction is LONG via proxies (SMH/KWEB) on the idea that regional trade acceleration (semis plus new energy) can be an early throughput indicator before broader macro consensus updates. The market tends to anchor on national prints; regional ...
FCC Conditional Approval as a Supply-Chain Tax: A Router ‘Ban’ That’s Really About New Models and...
The direction is SHORT on proxy exposure because the mechanism is regulatory friction: conditional approvals and import constraints function like a compliance tax that can disrupt new-model cadence, raise costs, and create near-term uncertainty ac...
Medpace litigation noise, now with entity confusion: treat 'Merit Financial' as a propagation bug...
This is the same underlying economic story as the Medpace lawsuit cluster, with an extra twist: an entity-role attribution problem that can itself fuel sloppy propagation. That matters because markets often trade the headline before they trade the...
REPL: when a CRL becomes layoffs, the equity story turns into runway maths
This is a SHORT on REPL because the thesis is not “FDA letter bad” in isolation; it is “regulatory setback plus operational retrenchment” implying higher dilution probability and lower platform optionality. The mechanism sign is negative with medi...
Ixchiq Safety Overhang Keeps Reappearing - Valneva Trades the Uncertainty, Not the Data
This is a clean safety and regulatory restriction story, which is almost always bearish for a small-cap vaccine name: once regulators recommend a pause or impose restrictions, the commercial narrative turns into an overhang of uncertain duration. ...
Korea’s AI Substrate Mania: If FC-BGA Tightness Is Real, the Upside Is Structural, Not Just a Tar...
The call is LONG on the provided instrument because the mechanism is supplier upside leverage: AI build-outs are pulling forward demand for key components, and FC-BGA substrate narratives are one of the cleanest “picks-and-shovels” expressions of ...
Botulism recall: the event is real, the investable mapping is not (yet)
This is a SHORT default-proxy expression (SPY) of a high-severity recall signal because contamination narratives can expand from a small brand into wider retailer/manufacturer scrutiny if distribution is broader than first reported. Mechanically, ...
The Alzheimer's bear case is not new data - it's a reimbursement headline waiting to happen
This is a SHORT proxy call via IHE because the “no clinically meaningful effect” framing can travel faster than any technical rebuttal and become payer/policymaker ammunition. The mechanism is narrative-to-reimbursement: if the framing sticks, it ...
Lupin Form 483: the short works if you know which site - otherwise it's just noise
This is a SHORT on Lupin because Form 483 issuance is the first public marker that manufacturing controls may have failed FDA expectations, and the tail risk is escalation to warning letter/import constraints. The mechanism is remediation cost and...
Pfizer gets a new Outperform initiation: it's probably dissemination, but dissemination can still...
This is a classic "opinion distribution" catalyst: a new initiation (especially if it travels through aggregators) can shape sentiment and create follow-on coverage even if it adds no new facts. The direction is LONG because the system judges the ...
Roundup Liability Keeps Bayer's Left Tail Fat - Legal Milestones Do Not Remove The Overhang Overn...
The economic exposure is Bayer via Monsanto's Roundup litigation, and the short case is structurally simple: a large, persistent legal overhang creates downside skew, and each procedural milestone can re-price expected liability, timelines, and se...
The 'Danielle Peyton' investigation signal is tradable only after you find the issuer
This is a SHORT proxy call via XBI because the mechanism is litigation/disclosure overhang, but the current instantiation is structurally fragile: person-name-led “investigation” items often fail to name the issuer clearly. The bearish direction i...
Psychedelic stocks surging is exactly why the right trade may be short XBI
This is a SHORT proxy call via XBI because the risk is classic narrative overshoot: “EO means fast-track” gets priced as certainty, then reality arrives as a slower, procedural implementation. The mechanism is valuation volatility outrunning imple...
California enforcement 'availability issues': real policy energy, weak ticker mapping - the SPY p...
The underlying idea is that state-level enforcement can create sudden availability shocks in specific product categories and can be a marker of a tougher regulatory posture that bleeds into broader narratives. The system still calls this SHORT, bu...
Morepen compliance signal flips bullish on the artefact - but 7A still keeps the SHORT as a risk-...
The interesting tension here is internal: 6B framed this as negative compliance risk optionality, while 7.2 research (as referenced in the 7A rationale note) reportedly leaned bullish on the most concrete artefact. 7A nonetheless holds the directi...
Medicaid audit expansion: a quiet compliance shock that markets rarely price early
This is a SHORT default-proxy call (SPY) because the mechanism is payment-friction and compliance cost: broad provider revalidation and expanded audits can slow billing cycles, increase recoupment risk, and push “clean up your house” behaviour acr...
California enforcement 'availability disruption' is bearish - but only after you name the product
This is a SHORT default-proxy call because “enforcement-driven availability issues” is structurally bearish for any category that depends on California distribution and compliance. The mechanism is simple: enforcement removes inventory, then suppl...
REGENXBIO Gets A Rare Tailwind: A Precedential Patent-Eligibility Win That Can Re-Rate Platform E...
This is a clean legal-to-valuation signal: patent eligibility clarity, framed as favourable to REGENXBIO-linked gene therapy claims. 7A is LONG: the economic mechanism is that stronger eligibility precedent improves IP defensibility, raises expect...
OpenAI drug-discovery acceleration: the story is loud, the deployments are quiet - but biotech be...
AI-enabled productivity narratives are one of the few cross-issuer stories that can re-rate a whole cohort quickly if they feel credible, and the system keeps this LONG because the mechanism is simple: if investors believe discovery timelines comp...
A Massive FCA Judgment And An Article II Challenge Is A Real Overhang For Janssen - And JNJ Carri...
This is a litigation-overhang trade expressed via JNJ as proxy for Janssen exposure. 7A is SHORT: the near-term mechanism is not a theoretical constitutional debate, it is the weight of a very large FCA judgment plus appellate uncertainty. That ki...
SK Hynix Prints a 72% Operating Margin - The Trade Is Easy, the Edge Isn't
The directional call is LONG: the company itself has now put up the kind of HBM-led profitability that reframes hynix from "memory cycle" to "AI bottleneck owner". The print is record-level and the mechanism is clean in the primary disclosure: mix...
AMD stays a LONG, but the edge is now about timing and constraints, not discovery
The call remains LONG because the mechanism is still supplier-positive: AI infrastructure investment converting into shipped revenue is constructive for AMD. The reason this is INVESTIGATE is not directional doubt, it is edge decay: the signal is ...
Photonics funding is real, but the trade edge is closing: turn it into recipient-level specificit...
The direction remains LONG because the mechanism is supportive: photonics and co-packaged optics funding can accelerate a technology stack that ultimately matters for AI-scale interconnects. The reason this is INVESTIGATE is edge decay: the upstre...
Samsung-Qualcomm S27 chip chatter has already hit Bloomberg; the edge is closing, but the directi...
Upstream direction is LONG: the mechanism is supplier-side positioning around next-generation Snapdragon chips tied to Samsung's Galaxy roadmap, which can be read as a positive signal for Samsung's ecosystem positioning. The reason this is INVESTI...
FDA Scrutiny + Class-Action Cluster: Real Filings, But the Edge Is Already Bleeding Out
The mechanism is straightforward and bearish for the group: a cluster of regulatory scrutiny headlines and securities class-action activity raises perceived disclosure and trial-integrity risk, which can widen discount rates for high-duration heal...
On-device AI growth is a bullish Intel narrative, but it is already everywhere
The direction remains LONG upstream: if on-device AI adoption accelerates, Intel benefits as a CPU/NPU supplier through mix and attach into the AI PC cycle. The problem is edge, not thesis: this is in propagation_monitor with a decaying informatio...
Texas grid constraint narratives are bearish for hyperscaler timing, but Microsoft is not a clean...
Upstream is SHORT: the mechanism is that grid and interconnection constraints can push out data-centre commissioning timelines, turning AI capex into a slower revenue recognition story with potential cost creep. The reason this stays INVESTIGATE i...
TSMC 'AI drives growth' is true, but it is not an edge; the trade now needs a new incremental dat...
The direction is LONG: AI-driven wafer and packaging demand is a structurally positive mechanism for TSMC. The reason this is INVESTIGATE is lifecycle: the signal is explicitly in propagation_monitor with a decaying information edge, meaning the m...
Google Cloud capex is still a LONG tailwind for semis, but you are late: investigate constraints,...
The direction is LONG because hyperscaler expansion and capex support semiconductor demand through servers, networking, accelerators, and memory. The reason it is INVESTIGATE is that the edge is decaying: upstream explicitly tags it as spreading w...
Intel miss-risk is now a mainstream talking point, but the downside sensitivity is still real
Upstream direction is SHORT: the mechanism is straightforward earnings downside sensitivity, which tends to matter disproportionately in a higher-volatility, crosswind-heavy tape. The reason this is INVESTIGATE rather than TRADE is that the story ...
ASML Layoffs Are Everywhere Already: The Only Remaining Edge Is Whether Execution, Not Demand, Ta...
Directionally, the pipeline’s view is SHORT, but this sits in INVESTIGATE because the edge is already decaying: the job-cut story is broad and widely repeated. The only tradable residue is second-order: whether restructuring creates real throughpu...
Dato-DXd 'Dose Optimisation' Is Either Routine Or A Quiet Safety Constraint - You Need One Artifa...
The signal is about interpretation: 'dose optimisation and safety monitoring' around datopotamab deruxtecan (Dato-DXd). This is INVESTIGATE because 7A keeps direction MIXED - the same phrase can mean routine Project Optimus-era diligence (neutral)...
China HBM Catch-Up Slips Again: Bullish for Nvidia If It’s a Competitor Delay, Bearish if It Beco...
The directional stance remains LONG: if CXMT’s HBM3 ramp is delayed, competitive pressure from a China domestic memory push is pushed out, which supports the incumbent AI stack economics that Nvidia sits on top of. This is in INVESTIGATE because t...
FDA Litigation Clusters: Direction Is Short, But The Edge Is Closing - You Are Paying For Timing Now
The mechanism is straightforward: FDA-linked litigation narratives can function like a volatility tax on biotech/pharma, widening risk premia and compressing valuations. 7A is directionally SHORT, but this is INVESTIGATE because it is in propagati...
Dialysis-Kit Safety Claims Are Directionally Short, But The Bloomberg-Tier Pickup Means You Need ...
This is a safety/enforcement narrative that 7A calls SHORT, expressed via a pharma proxy, but it sits in propagation_monitor with decaying edge. That matters: the 'headline' is already in a Tier-1 channel upstream, so the advantage is no longer di...
Korea’s AI-ASIC Funding Boom Is Already Public: The Only Edge Left Is Whether It Produces Real Wa...
The directional argument is LONG: more funded AI-ASIC entrants in Korea can expand the ecosystem that ultimately consumes HBM and advanced packaging, which is supportive for SK Hynix over time. But this is INVESTIGATE, not TRADE, because the story...
AWS-Anthropic ‘Massive Commitments’ Are Now Wallpaper: Without Contract Terms, It’s Just a Fade
This is AVOID (FADE) because the compute-commitment narrative is mainstream and the only remaining debate is interpretation, not discovery. Directionally that means MIXED: headline “commitment” numbers do not map cleanly to profit without contract...
Nitrosamines in combination products: the warning is real, the trade mapping is missing
The underlying issue is a classic quality surprise vector: nitrosamine impurity awareness expanding into device-drug combination products, which historically can migrate from technical letters into sudden product-specific actions once pathways and...
SpaceX 'in-house GPU manufacturing' is already a crowded story, and the mechanism splits both ways
This one is directionally MIXED and routed to propagation_monitor, which is why it is AVOID: the story has spread into Tier-1 domains upstream and the economic mechanism genuinely splits. If it is demand substitution (SpaceX buys fewer third-party...
The FCC-TP-Link router squeeze is a real policy shock, but it is non-tradeable here: do not force...
The direction is SHORT because the mechanism is supplier-negative: a regulatory approval bottleneck can disrupt new product cycles and distort channel dynamics. The problem is instrumentability: upstream did not bind a listed equity or proxy, so t...
Amazon AI capex expansion is a two-sided equity story, and the edge is already gone
This is MIXED and in propagation_monitor, so it is AVOID: AI infrastructure expansion can be positive for the supply chain and AWS growth, but it can also be negative for Amazon equity near-term if it raises capex burden and compresses cash flow. ...
Oman drops a 100k tpy polysilicon headline into a China-dominated market, but you cannot trade it...
The mechanism is supplier-positive at the supply-chain level: a large non-China polysilicon facility can reshape diversification narratives and, if the ramp is real, influence supply and pricing dynamics. Upstream keeps the directional sign LONG b...
Lilly 'Compliance' Is Already In The Tape - And This Payload Is Directionally Unresolved
This signal is in propagation_monitor with a decaying edge: Tier-1 pickup is present upstream, and 7A keeps direction MIXED. The underlying idea is that a 'regulatory compliance' narrative around a mega-cap like Lilly can matter, but only when it ...
State AGs are trying to use payments rails as enforcement - but you have no instrument bound
The directional mechanism is bearish for payments and platforms: if enforcement pressure causes processors/acquirers to terminate merchants, compliance cost and reputational risk rise and the ecosystem tightens. That is a real mechanism. The reaso...
ON Semiconductor expansion: single-source, non-tradeable in this run
ON Semiconductor's expansion reads as supplier-positive: a brownfield capacity increase supported by local incentives can matter for regionally exposed product lines. Upstream flags this as a single-source item and the pipeline did not bind a trad...
When the Ticker Doesn’t Match the Thesis: The AMD ‘Surge’ Narrative Is Now a Fade, Not a Fresh Si...
This was flagged as “AMD data centre revenue surge”, but it is now an AVOID because the edge is gone and the mapping is messy: the pipeline itself marks this as FADE in propagation_monitor, and the instrument binding sits on MSFT while the economi...
A Real Science Paper, a Real Constraint, and No Clean Ticker: The 2D Materials ‘Reality Check’ Is...
The direction is SHORT in concept: TU Wien is arguing that a van der Waals interface “gap” imposes a hard performance/scaling penalty for 2D semiconductor stacks, which compresses the hype premium around near-term 2D materials roadmaps. But this i...
‘Nasdaq Rally Because AI’: A Narrative Everyone Already Has, With No Incremental Mechanism to Trade
This is now an AVOID because it is explicitly a FADE-class item: the information edge is gone, and the remaining content is just a broad label (“AI + geopolitics easing”) applied to index movement. Directionally, that means MIXED (no exposure), no...
Apple Earnings Calendar Is Not an Edge: This Is a Fade Until a Real Channel/Supply Signal Appears
This is AVOID (FADE) because “upcoming macro and earnings events” is by definition public and already reflected in positioning. Directionally, that means MIXED: there is no informational edge here, only a volatility window. If you want an Apple ed...
A 'clean USFDA inspection streak' is bullish - but this is still single-source and untradeable here
Directionally this is bullish: repeated clean inspections reduce manufacturing-regulatory tail risk, and that can support export continuity and contracting narratives for an India-based manufacturer. The reason it matters for global pharma investo...